Navidea Biopharmaceuticals (NAVB) Competitors $0.0008 0.00 (0.00%) As of 02/21/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsOptions ChainSEC FilingsTrends NAVB vs. NEXI, HSTO, SMFL, SCPS, VAXX, EVLO, CMRA, GNCA, ARDS, and CALAShould you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include NexImmune (NEXI), Histogen (HSTO), Smart for Life (SMFL), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry. Navidea Biopharmaceuticals vs. NexImmune Histogen Smart for Life Scopus BioPharma Vaxxinity Evelo Biosciences Comera Life Sciences Genocea Biosciences Aridis Pharmaceuticals Calithera Biosciences Navidea Biopharmaceuticals (NYSE:NAVB) and NexImmune (NASDAQ:NEXI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends. Does the media prefer NAVB or NEXI? In the previous week, Navidea Biopharmaceuticals had 1 more articles in the media than NexImmune. MarketBeat recorded 1 mentions for Navidea Biopharmaceuticals and 0 mentions for NexImmune. Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled NexImmune'saverage media sentiment score. Company Overall Sentiment Navidea Biopharmaceuticals Neutral NexImmune Neutral Does the MarketBeat Community prefer NAVB or NEXI? NexImmune received 22 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 61.11% of users gave NexImmune an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformNavidea BiopharmaceuticalsOutperform VotesNo VotesUnderperform Votes76100.00% NexImmuneOutperform Votes2261.11% Underperform Votes1438.89% Which has better valuation and earnings, NAVB or NEXI? Navidea Biopharmaceuticals has higher revenue and earnings than NexImmune. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNavidea Biopharmaceuticals$70K1.14-$15.18MN/AN/ANexImmuneN/AN/A-$32.34M-$18.54-0.01 Do institutionals & insiders hold more shares of NAVB or NEXI? 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 9.9% of NexImmune shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 14.9% of NexImmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, NAVB or NEXI? Navidea Biopharmaceuticals has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, NexImmune has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Is NAVB or NEXI more profitable? Navidea Biopharmaceuticals' return on equity of 0.00% beat NexImmune's return on equity.Company Net Margins Return on Equity Return on Assets Navidea BiopharmaceuticalsN/A N/A N/A NexImmune N/A -534.32%-213.72% SummaryNavidea Biopharmaceuticals beats NexImmune on 7 of the 10 factors compared between the two stocks. Get Navidea Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart NAVB vs. The Competition Export to ExcelMetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$80,000.00$2.30B$5.84B$20.30BDividend YieldN/A0.75%4.75%3.64%P/E RatioN/A5.0426.4934.89Price / Sales1.1462.84435.3715.49Price / CashN/A15.7538.0120.26Price / BookN/A3.287.644.80Net Income-$15.18M-$65.73M$3.19B$1.02B7 Day PerformanceN/A-4.01%-2.12%-1.07%1 Month PerformanceN/A-9.02%-0.45%-1.11%1 Year PerformanceN/A-15.61%16.26%13.69% Navidea Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-98.3%$80,000.00$70,000.000.0010Analyst ForecastNEXINexImmuneN/A$0.10-9.9%N/AN/A$139,000.00N/A-0.016HSTOHistogenN/A$0.03-5.9%N/A-93.3%$115,000.00$19,000.00-0.0120Gap DownHigh Trading VolumeSMFLSmart for LifeN/A$0.01-9.5%N/A-99.9%$67,000.00$11.11M0.00110Gap DownSCPSScopus BioPharmaN/A$0.00flatN/A-91.7%$13,000.00N/A0.009VAXXVaxxinityN/A$0.00flatN/A-99.3%$13,000.00N/A0.0090High Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/A-95.3%$9,000.00N/A0.00120Options VolumeNews CoverageCMRAComera Life SciencesN/A$0.00flatN/A-99.4%$6,000.00$630,000.000.002High Trading VolumeGNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastARDSAridis PharmaceuticalsN/A$0.00+∞N/AN/A$5,000.00$3.09M0.0030High Trading VolumeCALACalithera BiosciencesN/A$0.00flatN/A-97.0%$3,000.00N/A0.0060Analyst ForecastNews Coverage Related Companies and Tools Related Companies NexImmune Competitors Histogen Competitors Smart for Life Competitors Scopus BioPharma Competitors Vaxxinity Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Calithera Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NAVB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
